Search the Newsreel

Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY

Passage Bio (NASDAQ: PASG) reported stronger-than-expected Q2 results, with EPS of $(2.44), surpassing analyst estimates of $(3.47) by 29.68%. This performance also marked a 17.57% year-over-year improvement in losses compared to the previous year's $(2.96) per share deficit. The earnings beat suggests better cost …

Passage Bio Q2 net loss narrows 16.67% to $7.82 million

Passage Bio reported a Q2 net loss of $7.82 million, a 16.67% improvement from the previous year, with an operating loss of $8.27 million. Despite reduced R&D expenses, general and administrative costs rose. The company is winding down gene-therapy programs, terminating key contracts, and …

Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms

Passage Bio (PASG) reported a Q2 2026 net loss of $7.8 million and a six-month net loss of $15.4 million, with cash and cash equivalents declining to $24.2 million. The company disclosed substantial doubt about its ability to continue as a going concern without …

Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary

Passage BIO, Inc. reported a comprehensive loss and net loss of ($7.82M) for the quarter ended 2026, with a diluted loss per share of ($2.44), showing an improvement compared to the prior year. The company is undergoing significant changes including a merger agreement with …

Passage Bio (PASG) Earnings Date and Reports 2026

Passage Bio Inc expected to post a loss of $2.65 a share - Earnings Preview

Passage Bio Inc is projected to report a loss of $2.65 per share in its upcoming earnings announcement. This information is provided as an earnings preview. The full article from Reuters offers more details, which can be accessed through a TradingView subscription.

Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article from TradingKey provides an earnings forecast for Passage Bio Inc (PASG), detailing analyst ratings, target prices, and historical and projected EPS. Based on 3 analysts, the stock has a "Hold" rating with a target price of $15.50, representing a potential upside of …

Sage (LSE:SGE) Tests the Premium Placed on Dependable Software Income

Passage Bio Inc (PASG) Cash Flow

This article provides a detailed cash flow statement for Passage Bio Inc (PASG), presenting quarterly and annual figures for operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flows and their significance for investors. The data covers …

Passage Bio Inc (PASG) Income Statement

This article provides the quarterly and annual income statements for Passage Bio Inc (PASG), offering detailed financial data including operating expenses, R&D expenses, operating profit, and net income from Q1 2019 to Q1 2026. It also includes an FAQ section explaining how to read …

PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040

This article provides a detailed financial overview of Passage Bio Inc (PASG), including its stock performance, key financial indicators like EPS and net profit, and balance sheet and cash flow statements. It highlights the company's latest earnings release, analyst rating, and offers a quarterly …

Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG

PASG Q2'26 Earnings: revenue estimate is 0 USD

Passage Bio, Inc. (PASG) is scheduled to announce its Q2'26 earnings on July 30, 2026. The company is expected to report a revenue estimate of $0 USD and an EPS of ($2.65) USD for the quarter. Previous quarters' EPS and their respective surprises are …

Passage Bio (PASG) to merge with Remix in $100M-backed oncology deal

Passage Bio (PASG) is set to merge with Remix Therapeutics, forming a Nasdaq-listed company focused on Remix’s RNA-processing oncology pipeline, particularly targeting adenoid cystic carcinoma with REM-422. The deal includes an oversubscribed $100M concurrent financing, projecting the combined entity to be funded into the …

Form 4 Passage Bio Inc For: 22 July By Investing.com

This article from Investing.com is a regulatory filing update, specifically a Form 4 for Passage Bio Inc, dated July 22. It briefly mentions the company's stock performance, showing a 2.08% increase. The content is primarily a placeholder for the Form 4 information, with additional …

The Sage Group plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:SGPYY) 2026-05-21

Institutional owners may consider drastic measures as The Sage Group plc's (LON:SGE) recent UK£344m drop adds to long-term losses

Subdued Growth No Barrier To The Sage Group plc's (LON:SGE) Price

Estimating The Fair Value Of The Sage Group plc (LON:SGE)

Analyst Estimates: Here's What Brokers Think Of The Sage Group plc (LON:SGE) After Its Annual Report